Resalis Therapeutics is a biopharma company that focuses on the development of oligonucleotide anti-sense therapies.
Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of key pathways underlying obesity and fatty liver disease.
Resalis Therapeutics was founded in 2021 by Riccardo Panella and Sakari Kauppinen. The company is headquartered in Turin, Piedmont, Italy.
Resalis is applying its unique understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis.
Resalis Therapeutics has raised €10M in a Seed funding on Feb 22, 2023. The round was led by Claris Ventures, with participation from Italian Angels for Growth and Club degli Investitori.